Treatment of severe nosocomial infections: doripenem - a new carbapenems antibiotic

Abstract

Doripenem is a new carbapenems antibiotic and takes an important place in the treatment of severe nosocomial infections, as well as in case of infections caused by multi-drug resistant microorganisms; and can be used for the treatment of complicated intraabdominal infection, complicated urinary tract infections (including bacteraemia), nosocomial pneumonia, including ventilator-associated pneumonia. The review presents the data of international studies concerning the determining the susceptibility of microorganisms to doripenem in vitro, including Pseudomonas aeruginosa, Acinetobacter and others, the results of pharmacokinetic and clinical studies with the drug. We discuss the approaches to overcome the microorganism resistance using prolonged infusion of doripenem, as well as antibiotic tolerance and pharmacoeconomic data.

Keywords

• pseudomonas aeruginosa
• acinetobacter baumannii
• doripenem
• carbapenems
• nosocomial infections
• multi-drug resistant microorganisms
• pseudomonas aeruginosa
• acineto-bacter baumannii